PDE4A and early-onset autosomal dominant Alzheimer disease: A PDE4 inhibitor Zatomilast® is currently in Phase III Clinical Trials for the treatment of cognitive deficits produced by Alzheimer’s disease and Fragile-X Syndrome, further demonstrating the importance of activating the cAMP/PKA pathway.